Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation

NCT01037608 | Completed Phase 1

• 2 other identifiers: 99990742307-DA-N423
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

Background:

• The therapeutic modalities of cannabis have received more research attention recently with the discovery of its ability to stimulate appetite and to provide pain and nausea relief in patients with AIDS, cancer, and multiple sclerosis, among other diseases. Sativex(Registered Trademark), an experimental drug derived from the marijuana plant, contains tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which affect brain activity. Sativex(Registered Trademark) is being tested to determine how and to what extent it affects brain activity.
• Functional magnetic resonance imaging (fMRI) uses magnetic waves to study brain activity. Researchers are interested in using fMRI to study how Sativex(Registered Trademark) affects regional brain activity, including thinking abilities and behavior. Objectives:
• To study changes in regional brain activity produced by Sativex(Registered Trademark) compared with THC and placebo.
• To determine how Sativex(Registered Trademark) is processed by the body. Eligibility: \- Individuals between 18 and 45 years of age who are either current users of cannabis (less than daily) or healthy volunteers who do not use cannabis. Design:
• The study will involve one training session and five testing sessions on separate days.
• At every session, subjects will receive either THC or placebo capsules and either Sativex(Registered Trademark) or placebo spray.
• Participants will complete a training session in a mock fMRI scanner to adapt to the fMRI scanning environment. In the training session, participants will practice the tests that will track thinking ability, attention, working memory, and other cognitive tasks.
• Participants will have five fMRI scanning sessions with the tests they have practiced previously, and will provide blood, urine, and saliva samples as required by the researchers. Participants will be discharged approximately 12 hours after they arrive for the study sessions....

Conditions

Cannabis; Dependence; Cannabis Abuse; Pharmacokinetics; fMRI

Keywords

Sativex; fMRI; Alternative Matrices; Brain Imaging; THC

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetics/Pharmacodynamics

Interventions

Sativex(Registered Trademark) DRUG

THC DRUG

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• to 45 years of age;
• Cannabis use with a minimum frequency of once in the last 90 days and maximum frequency of less than daily during the three months prior to study entry;
• Blood pressure (BP) and heart rate (HR) at or below the following values while sitting after five min rest: Systolic BP (SBP) 140 mm Hg, diastolic BP (DBP) 90 mm Hg, heart rate (HR) 100 bpm;
• lead standard ECG and three-minute rhythm strip without clinically relevant abnormalities;
• Peripheral veins suitable for repeated venipuncture and placement and maintenance of an IV catheter;
• Ability to swallow capsules;
• Ability to communicate well with the investigators and to comply with study requirements;
• If female with reproductive potential, must be using a reliable method of birth control or abstaining from vaginal sexual intercourse;
• Estimated IQ greater than or equal to 85 determined by the Wechsler Abbreviated Scale of Intelligence;
• Right-handed.

You may not qualify if:

• History or presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might put the subject at increased risk of adverse events or that might interfere with the absorption, distribution, metabolism, or excretion of study drugs. Clinically significant is defined as being likely to affect the safety of the subject during his/her participation in this trial, or preclude achievement of the protocol objectives.
• Current tolerance to any substance other than nicotine or caffeine;
• Positive serological tests for syphilis or HIV infection;
• Positive purified protein derivative (PPD) test in the absence of a negative chest X-ray;
• History of a clinically significant adverse event associated with cannabis intoxication or withdrawal;
• History of epileptic seizures or head trauma with loss of consciousness greater than three min;
• History of psychosis or any current DSM-IV axis I disorder (other than caffeine or nicotine dependence, or simple phobia);
• Family history of psychosis (except that related to acute drug intoxication) in a first-degree relative;
• Donation of more than 500 mL of blood within 30 days of study drug administration;
• Regular use of alcohol (greater than or equal to five standard drinks per day) four or more times per week in the month prior to study entry;
• If female, pregnant or nursing;
• ADHD Screening Rating Scale score greater than or equal to 24 on either the A or B subscale;
• Allergy to sesame seed oil (ingredient in dronabinol capsules), propylene glycol, ethanol, or peppermint oil (ingredients in Sativex(Registered Trademark));
• Currently interested in or participating in drug abuse treatment, or participated in drug abuse treatment within 60 days preceding study enrollment.
• Claustrophobia that precludes being able to tolerate an fMRI session.

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA): lead

Study Sites (1)

National Institute on Drug Abuse, Biomedical Research Center (BRC)

Baltimore, Maryland, 21224, United States

Location

Related Publications (3)

• Vega WA, Aguilar-Gaxiola S, Andrade L, Bijl R, Borges G, Caraveo-Anduaga JJ, DeWit DJ, Heeringa SG, Kessler RC, Kolody B, Merikangas KR, Molnar BE, Walters EE, Warner LA, Wittchen HU. Prevalence and age of onset for drug use in seven international sites: results from the international consortium of psychiatric epidemiology. Drug Alcohol Depend. 2002 Dec 1;68(3):285-97. doi: 10.1016/s0376-8716(02)00224-7.

  PMID: 12393223 BACKGROUND

• Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001 Apr;58(4):322-8. doi: 10.1001/archpsyc.58.4.322.

  PMID: 11296091 BACKGROUND

• Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997 May 15;126(10):791-8. doi: 10.7326/0003-4819-126-10-199705150-00008.

  PMID: 9148653 BACKGROUND

MeSH Terms

Conditions

Marijuana Abuse

Interventions

Dronabinol

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Cannabinoids; Terpenes; Hydrocarbons; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: NIH

Study Record Dates

• First Submitted: December 19, 2009
• First Posted: December 23, 2009
• Study Start: May 8, 2007
• Primary Completion: August 15, 2011
• Study Completion: December 12, 2011
• Last Updated: July 2, 2017

Record last verified: 2011-12-12

Locations

US (1)